Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ATRN-119

Small molecule · Inhibitor of ataxia telangiectasia and Rad3 related protein kinase (ATR) · developed by Aprea Therapeutics

Phase 1/2 Most advanced trial
APRE Developer
1 Registered trials

What is ATRN-119?

ATRN-119 (mosipasertib) is an orally bioavailable inhibitor of the ATR kinase, a DNA damage response protein. It binds ATR and blocks downstream CHK1 phosphorylation, disrupting DNA damage checkpoint activation and repair and inducing tumor cell apoptosis. It is being studied in HPV-positive oropharyngeal squamous cell carcinoma and other HPV-associated carcinomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Mosipasertib
Drug type
Small molecule
Targets
ataxia telangiectasia and Rad3 related protein kinase (ATR)
Mechanism
Inhibitor of ataxia telangiectasia and Rad3 related protein kinase (ATR)
Pathways
DNA damage response, CHK1 phosphorylation and checkpoint signaling, DNA repair, apoptosis
Therapy area
Oncology
Developer
Aprea Therapeutics (APRE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07578467 Phase 1/2 HPV Positive Oropharyngeal Squamous Cell Carcinoma Not yet recruiting APRE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HPV (Human Papillomavirus)-Associated CarcinomaHPV Associated CancersHPV Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal HPV Squamous Cell CarcinomaSquamous Cell Carcinoma

Other drugs acting on ATR

More from Aprea Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the APRE page.

Follow APRE, the company behind ATRN-119

See APRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APRE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.